L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)

Summary

Although there is a strong rationale to supplement gravid patients suffering intrauterine growth restriction (IUGR) or preeclampsia with Arginine or other nitric oxide donors, evidence in the literature has been inconclusive. The current study was designed to determine whether oral treatment with L-Arginine, a nitric oxide (NO) donor, would enhance birth weight and/or decrease neonatal morbidity in pregnancies with severe vascular intrauterine growth restriction (IUGR).

Timeline

Start

2000-07

Primary completion

—

Completion

2006-06

Outcome

Missed primary endpoint

Stopped: “terminated”

paper There was no significant difference between the two groups concerning birth weight (1042+/-476 vs. 1068+/-452 g). PMID 19359073 ↗

paper L-arginine is not an effective treatment for severe vascular growth restriction. PMID 19359073 ↗

Publications

• Winer N, Branger B, Azria E, Tsatsaris V, Philippe HJ, Roze JC, Descamps P, Boog G, Cynober L, Darmaun D. L-Arginine treatment for severe vascular fetal intrauterine growth restriction: a randomized double-bind controlled trial. Clin Nutr. 2009 Jun;28(3):243-8. doi: 10.1016/j.clnu.2009.03.007. Epub 2009 Apr 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ARGININE	Small molecule	14 g	Oral

Indications